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Interplay between HDAC3  
and WDR5 is essential for  
hypoxia-induced epithelial–
mesenchymal transition
Wu et al., Mol Cell 2011; 43: 811–822; doi:10.1016/j.molcel.2011.07.012
Chronic hypoxia of the tubulointerstitium is a final common path-
way to fibrosis of the kidney and end-stage kidney failure. Epithe-
lial–mesenchymal transition (EMT) has been studied intensively 
as a mechanism by which injured renal tubular cells transform into 
mesenchymal cells that contribute to the development of fibrosis in 
chronic kidney failure. While recent studies raise doubts about the 
involvement of this process in fibrosis of the kidney in vivo, EMT 
is clearly important for development of cancer. Hypoxia is also a 
feature of most tumors, and because tumor vessels are structurally 
and functionally abnormal, even highly vascularized cancers suffer 
from severe hypoxia.
Wu and colleagues studied molecular mechanisms to coordi-
nately regulate hypoxia-induced EMT in cancer cell lines. They 
used a bioinformatic approach and identified histone deacetylase 
3 (HDAC3) as a downstream target of hypoxia-inducible factor 
1 (HIF-1). Histone acetylation is associated with transcriptional 
activation, and epigenetics provides an extra layer of transcrip-
tional control. Repression of HDAC3 by siRNA caused the shift in 
expression of mesenchymal markers to epithelial markers. Change 
of specific chromatin states was associated with hypoxia-induced 
EMT. Quantitative chromatin immunoprecipitation assays showed 
that HDAC3 bound to the promoters of epithelial genes in hypoxic 
clones, which correlated with decreased histone H3 lysine 4 
(H3K4) acetylation. These results showed that hypoxia suppressed 
expression of epithelial genes by histone deacetylation. Under 
hypoxia, HDAC3 also interacted with hypoxia-induced WDR5, 
a common component of the histone methyltransferase (HMT) 
complex. The effects of histone methylation on gene expression are 
more complex than those of acetylation, and methylation of H3K4 
results in activation of transcription whereas methylation of H3K9 
is characteristic of inactivation of transcription. HDAC3 recruited 
the HMT complex to increase H3K4-specific HMT activity and 
increased H3K4me2 levels on the mesenchymal gene promoters 
in association with activation of mesenchymal gene expression 
under hypoxia. Knock-down of WDR5 abolished mesenchymal 
gene activation during hypoxia. These results showed that hypoxia 
enhanced expression of mesenchymal genes by regulating histone 
methylation (Figure).
The authors’ results indicate that hypoxia induces different chro-
matin modifiers to coordinately regulate EMT, at least in cancer 
cells. Advances in epigenome research may lead to identification 
of novel therapeutic targets in fibrotic diseases.
Masaomi Nangaku
Early events and late graft  
outcome: identifying the 
transplant’s ill humors
Moreso et al., Transplantation 2012; 93: 41–46; doi:10.1097/
TP.0b013e31823bb647
One of the major unmet challenges in renal transplantation is the 
development of treatment strategies to prevent chronic antibody-
mediated allograft injury. Key to tackling this problem is the iden-
tification of early risk factors for its development, which might 
allow the development of novel therapeutic strategies. Moreso et 
al. provide important new insight into the development of chronic 
humoral rejection in a prospective renal allograft protocol biopsy-
based study, by linking early biopsy changes to later transplant 
biopsy pathology. Of 517 patients with a renal allograft protocol 
biopsy, 109 underwent subsequent biopsy for cause, of whom 
40% had features of chronic humoral rejection (CHR) and 38% 
had interstitial fibrosis and tubular atrophy (IF/TA). Subclinical 
rejection in protocol biopsies was defined as an i-score or t-score 
more than or equal to 1, and protocol biopsies were not used for 
the clinical management of patients; thus subclinical rejection 
episodes were untreated. The major finding was the association 
between interstitial infiltrate and late CHR. In patients who went 
on to develop CHR, the severity of the interstitial inflammation 
and tubulitis present on the protocol biopsy was twofold higher 
than in patients who went on to develop IF/TA. In logistic regres-
sion analysis, subclinical rejection was a better predictor of CHR 
(relative risk 2.52, 95% confidence interval 1.1–6.3, P = 0.047) than 
the well-known risk factor of retransplantation. Patients with CHR 
had significantly poorer death-censored graft survival than those 
with IF/TA alone, including patients with CHR who stained nega-
tive for C4d on biopsy.
The study had several limitations, including a lack of data on the 
prevalence of HLA antibodies at the time of biopsy for cause, as 
just over 50% of patients had a serum sample available for analysis 
by Luminex, limiting the data available on the role of antibody in 
the late graft pathology. Nevertheless, it adds to the body of litera-
ture supporting the role of protocol biopsies as safe and potentially 
useful tools for transplant management. The next clinical research 
step will be to design trials to treat subclinical rejection to impact 
long-term graft survival.
P. Toby Coates
HDAC3 at the fulcrum of an epithelial–mesenchymal balance. 
(Reprinted from Mani SA, Barton MC. HDAC at the fulcrum of an 
epithelial-mesenchymal balance. Mol Cell 2011; 43: 697–698.)
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No coronary artery calcification =  
no coronary artery disease?
Villines et al., J Am Coll Cardiol 2011; 58: 2533–2540; doi:10.1016/j.
jacc.2011.10.851
Vascular calcification has become a widely accepted surrogate 
marker for atheromatous vascular disease in the general popula-
tion. Specifically, coronary artery calcification (CAC), as quan-
tified by the CAC score with the use of noncontrast computed 
tomography, is considered by many to reflect the total coronary 
atherosclerotic burden. Therefore, it has been proposed as a 
risk marker for cardiovascular events, as it can be obtained by a 
noninvasive procedure. In asymptomatic patients, a CAC score 
near zero is associated with very low adverse-event rates. The 
addition of CAC score to traditional risk factors predicts adverse 
cardiovascular events more precisely than standard cardiovas-
cular risk factor scoring alone. Among symptomatic patients, 
the absence of CAC is associated with a very low risk of future 
cardiovascular events. Thus, patients with symptoms atypical 
for coronary ischemia and without CAC might avoid invasive 
evaluation for obstructive coronary artery disease (CAD). 
However, other experts question this approach. As the preva-
lence of obstructive CAD is not well known among patients 
with CAC scores of zero, who are at relatively low clinical risk 
of obstructive CAD, Villines et al. studied 10,037 symptomatic 
patients with suspected, but not known CAD who underwent 
both coronary computed tomography angiography (CCTA) and 
CAC scoring. CAD was assessed as <50%, ≥50%, and ≥70% ste-
nosis. Mean age was 57 years, and 51% had a CAC score of zero. 
Among patients with a CAC score of zero, 84% had no CAD, 
13% had nonobstructive stenosis, and 3.5% had ≥50% stenosis 
(1.4% had ≥70% stenosis) on CCTA. During a median of 2.1 
years, there was no difference in mortality among patients with 
a zero CAC score irrespective of obstructive CAD. Among 8907 
patients with follow-up for a composite cardiovascular end point 
(mortality, myocardial infarction, and late coronary revascu-
larization), 3.9% with a CAC score of zero and ≥50% stenosis 
experienced an event compared with 0.8% of patients with a 
CAC score of zero and no obstructive CAD (Figure). In this 
patient symptomatic cohort without known CAD and chronic 
kidney disease, CAC scoring did not add incremental prognostic 
information to CCTA.
The possible significance of this observation for patients with 
chronic kidney disease who have a much higher prevalence and 
more complex types of vascular calcification remains to be seen.
Tilman B. Drüeke
Acute kidney injury in patients  
with acute lung injury: impact 
of fluid accumulation on 
classification of acute kidney 
injury and associated outcomes
Liu et al., Crit Care Med 2011; 39: 2665–2671; doi:10.1097/
CCM.0b013e318228234b
One major difficulty in interpreting the results of observational 
and interventional studies in patients with acute kidney injury 
(AKI) was the lack of a consistent definition of the injury. This 
led to the introduction of the RIFLE staging criteria for AKI, 
later revised by the AKIN group to include both an absolute rise 
in serum creatinine of at least 0.3 mg/dl (AKI-1) and a 48-hour 
time frame for the creatinine changes. Although these classifica-
tions have been shown to robustly predict patient mortality in 
diverse clinical settings, they have been criticized because they 
depend on a change in serum creatinine. Baseline creatinine has 
been debated, as patients may not have previous results, and the 
serum creatinine often changes between initial presentation and 
that following fluid resuscitation. Liu and colleagues reanalyzed 
changes in serum creatinine during the first 8 days in patients 
entered into the Acute Respiratory Distress Syndrome Network 
fluid and catheter trial, a trial of liberal versus conservative fluid 
management in patients monitored with either central venous or 
pulmonary artery catheters. The incidence of AKI was calculated 
with the AKI-1 classification, and then recalculated by correction 
of creatinine according to cumulative fluid status divided by total 
body water at the time of randomization, assuming this to be 60% 
of total body weight. Before adjustment of serum creatinine, 51% 
of the liberal fluid group developed AKI stage 1 compared with 
57% of the conservative group, but this reversed following adjust-
ment for cumulative fluid balance—66% of the liberal versus 58% 
of the conservative group. Mortality was 12% among patients 
without AKI and 11% among those who initially met the criteria 
for AKI-1 but did not fulfill the creatinine rise after cumulative 
volume adjustment, whereas the mortality of those who did not 
initially meet AKI-1 criteria but did so after volume adjustment 
was 31%. Patient mortality was 38% among those who had AKI-1 
on both assessments.
Changes in volume status impact serial creatinine measure-
ments and thus staging of AKI. As increases in serum creatinine 
and volume overload both predict mortality, patients with AKI and 
volume overload have a poor prognosis.
Andrew Davenport
Major adverse events stratified by the presence (pos.) or absence 
(zero) of CAC and <50% or ≥50% stenosis on CCTA.
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